Doravirine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Doravirine
Doravirine structure.svg
Clinical data
Trade names Pifeltro
Synonyms MK-1439
Routes of
administration
Oral[1]
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
ECHA InfoCard 100.234.454 Edit this at Wikidata
Chemical and physical data
Formula C17H11ClF3N5O3
Molar mass 425.75 g/mol
3D model (JSmol)

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. Doravirine demonstrated robust antiviral activity and good tolerability in a small clinical study of 7-day monotherapy reported at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013. Doravirine appeared safe and generally well-tolerated with most adverse events being mild-to-moderate.[2][3] In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo).[4]

References[edit]